⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Two GLP-1 medications dominate India's market for weight management and type 2 diabetes: semaglutide (brand names Ozempic for weekly injection, Rybelsus for daily oral tablet) and tirzepatide (brand name Mounjaro). Choosing between them is among the most frequent conversations in Indian metabolic clinics today. This guide summarises the key differences in plain language so you can have an informed conversation with your doctor. Consult your healthcare provider before starting any medication.
Semaglutide is a GLP-1 receptor agonist (GLP-1 RA). It mimics glucagon-like peptide-1, a natural gut hormone that:
Available in India as:
Tirzepatide is a dual GIP and GLP-1 receptor agonist — often called a "twincretin." It activates two gut hormone pathways simultaneously:
The addition of GIP activity is why tirzepatide generally outperforms semaglutide in head-to-head comparisons.
Available in India as:
| Metric | Semaglutide 2.4 mg (STEP-1) | Tirzepatide 15 mg (SURMOUNT-1) |
|---|---|---|
| Average weight loss | ~14.9% of body weight | ~20.9% of body weight |
| Patients losing >15% | ~50% | ~67% |
| Patients losing >20% | ~32% | ~56% |
| Trial duration | 68 weeks | 72 weeks |
| Placebo-adjusted loss | ~12.4% | ~17.8% |
Tirzepatide at maximum dose consistently produces greater weight loss. The SURPASS-2 trial directly compared semaglutide 1 mg vs tirzepatide — tirzepatide won on both HbA1c reduction and weight loss at every dose tested (5, 10, and 15 mg).
Important caveat: These are population averages. Individual responses vary enormously. Some patients lose 5% on tirzepatide and 18% on semaglutide. Your doctor cannot predict your individual response in advance — there is genuine trial-and-error in GLP-1 therapy.
| Metric | Semaglutide 1 mg | Tirzepatide 15 mg |
|---|---|---|
| Average HbA1c reduction | ~1.5–1.8% | ~2.0–2.3% |
| Patients achieving HbA1c below 7% | ~66% | ~82% |
| Fasting glucose reduction | ~1.4 mmol/L | ~2.4 mmol/L |
For Indian patients with poorly controlled type 2 diabetes who also want significant weight loss, tirzepatide's superior blood sugar control data is clinically compelling.
Both medications share similar side effects because both activate GLP-1 receptors.
| Side Effect | Semaglutide | Tirzepatide |
|---|---|---|
| Nausea | ~44% (usually mild–moderate) | ~44% (usually mild–moderate) |
| Vomiting | ~24% | ~25% |
| Diarrhoea | ~30% | ~23% |
| Constipation | ~24% | ~24% |
| Hair loss | ~3% | ~5.7% |
| Injection site reactions | ~3–5% | ~5–8% (higher doses) |
| Gallbladder problems | ~2% | ~1.9% |
| Hypoglycaemia (in non-diabetics) | Very rare | Very rare |
Tirzepatide's higher dose volumes (particularly at 15 mg) are associated with slightly more injection site reactions. Both drugs are weekly injectables — except Rybelsus (semaglutide oral), which is daily.
Semaglutide (Ozempic) — weekly injection:
Semaglutide (Rybelsus) — daily oral tablet:
Tirzepatide (Mounjaro) — weekly injection:
Rushing the tirzepatide escalation causes severe nausea. Some Indian patients try to accelerate to 15 mg in 8 weeks — this typically results in incapacitating vomiting and medication abandonment.
| Medication | Dose | Approx. Monthly Cost |
|---|---|---|
| Rybelsus 7 mg (oral) | Daily | ₹4,000–6,000 |
| Rybelsus 14 mg (oral) | Daily | ₹6,000–7,500 |
| Ozempic 0.5 mg pen | Weekly | ₹8,000–10,000 |
| Ozempic 1 mg pen | Weekly | ₹10,000–14,000 |
| Mounjaro 5 mg pen | Weekly | ₹12,000–15,000 |
| Mounjaro 10 mg pen | Weekly | ₹16,000–20,000 |
| Mounjaro 15 mg pen | Weekly | ₹18,000–22,000 |
Prices vary by pharmacy, city, and availability. Both have been declining year over year. No Indian insurance covers either medication as of 2026. Generic Indian versions of semaglutide are under regulatory review.
Semaglutide (Ozempic / Rybelsus) may be better if:
Tirzepatide (Mounjaro) may be better if:
1. Choosing based on what a friend is using. GLP-1 response is highly individual. The drug giving your colleague 22% weight loss may give you 7% — and vice versa. Personalised prescription, not social media popularity, should guide the choice.
2. Starting on the wrong dose. Both drugs have mandatory slow titration. Patients who try to start at therapeutic dose because "the titration doses don't do anything" typically end up with severe GI side effects and abandon the medication.
3. Switching after only 4–6 weeks. Most metabolic specialists consider 12–16 weeks the minimum before assessing a drug's response. Starting dose phases are not the therapeutic phase.
4. Ignoring diet and exercise. Clinical trial data showing 15–21% weight loss was achieved with dietary counselling and lifestyle advice alongside medication. The medication alone, without protein optimisation and exercise, produces significantly less weight loss.
5. Buying from unverified sources. Counterfeit and compounded versions of both semaglutide and tirzepatide circulate online in India. They carry risks of incorrect dosing, contamination, and infection. Purchase only from licensed pharmacies.
Your doctor may consider switching from semaglutide to tirzepatide after 6+ months if:
Switching does not require a washout period — start tirzepatide at its lowest dose (2.5 mg) the week following the last semaglutide injection.
Q: Is Mounjaro truly better than Ozempic? In clinical trials, tirzepatide at maximum dose outperforms semaglutide at its approved doses on both weight loss and HbA1c. However, population averages do not predict individual response. A patient may respond better to semaglutide for reasons not yet fully understood.
Q: Can I take both together? No. Combining two GLP-1 medications is not evidence-based, increases side effect risk dramatically, and would be considered off-label with no safety data to support it.
Q: My doctor prescribed Rybelsus but I want injections — can I switch? Yes — you can switch from oral Rybelsus to injectable Ozempic. Start injectable at 0.5 mg the day after your last Rybelsus dose. Discuss with your doctor first.
Q: Are compounded/generic versions safe? Compounded versions carry real safety risks — unknown purity, incorrect concentration, and absence of regulatory oversight. The brief price advantage does not justify these risks. Stick to pharmacy-dispensed, branded medications.
This article is for informational purposes only. Consult your healthcare provider before starting any medication or changing your current prescription.
